Migdal Insurance & Financial Holdings Ltd. C4 Therapeutics, Inc. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.18 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 02, 2022	SELL	$19.99 - $33.23 $12,093 - $20,104	-605 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$29.39 - $46.86 $17,310 - $27,600	-589 Reduced 49.33%	605 $20,000
Q3 2021 Nov 16, 2021	BUY	$35.91 - $50.5 $42,876 - $60,297	1,194 New	1,194 $53,000

Others Institutions Holding CCCC

# of Institutions

130

Shares Held

63.5M

Call Options Held

670K

Put Options Held

54.8K

Lynx1 Capital Management LP San Juan, PR

6.88M
Shares

$29.2 Million
14.04% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

6.6M
Shares

$28.1 Million
3.2% of portfolio
Wasatch Advisors Inc Salt Lake City, UT

5.68M
Shares

$24.1 Million
0.16% of portfolio
Ra Capital Management, L.P. Boston, MA

4.88M
Shares

$20.7 Million
0.39% of portfolio
Black Rock Inc. New York, NY

4.55M
Shares

$19.3 Million
0.0% of portfolio

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $208M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account